Statements (67)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:activities |
direct thrombin inhibitor
|
| gptkbp:administrative_division |
requires monitoring of a PTT
|
| gptkbp:appointed_by |
intravenous injection
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:bomb_load |
0.75 mg/kg
|
| gptkbp:brand |
gptkb:Angiomax
|
| gptkbp:clinical_trial |
Phase III
ACUITY trial ATLAS trial GUSTOIV trial HORIZONS-AMI trial ISAR-REACT 3 trial OASIS-5 trial REPLACE-2 trial TRACER trial during percutaneous coronary interventions effective in reducing major bleeding non-inferior to heparin |
| gptkbp:contraindication |
active bleeding
|
| gptkbp:developed_by |
gptkb:The_Medicines_Company
|
| gptkbp:education |
informed about bleeding risks
|
| gptkbp:effective_date |
gptkb:2000
|
| gptkbp:excretion |
renal
|
| gptkbp:financial_performance |
reconstituted solution stable for 24 hours
|
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:frequency |
continuous infusion
|
| gptkbp:healthcare |
injectable solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
bivalirudin
|
| gptkbp:indication |
percutaneous coronary intervention
|
| gptkbp:ingredients |
C58 H100 N12 O25 S
|
| gptkbp:interacts_with |
other anticoagulants
|
| gptkbp:invention |
patented
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
antithrombotic therapy
|
| gptkbp:lifespan |
25 minutes
|
| gptkbp:maintenance |
1.75 mg/kg/hour
|
| gptkbp:manager |
intravenous
|
| gptkbp:marketed_as |
gptkb:The_Medicines_Company
|
| gptkbp:metabolism |
plasma proteolysis
|
| gptkbp:pharmacokinetics |
gptkb:heparin
rapid onset of action inhibits thrombin activity |
| gptkbp:population |
patients undergoing PCI
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
gptkb:healthcare_organization
gptkb:American_College_of_Cardiology preferred over heparin in certain cases |
| gptkbp:regulatory_compliance |
approved in multiple countries
|
| gptkbp:research |
ongoing studies on long-term outcomes
|
| gptkbp:research_focus |
cardiovascular interventions
|
| gptkbp:safety_features |
generally well tolerated
required during administration |
| gptkbp:side_effect |
gptkb:fandom
nausea bleeding thrombocytopenia hypotension |
| gptkbp:social_structure |
gptkb:protein
|
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
thrombin
|
| gptkbp:traded_on |
gptkb:Angiomax
|
| gptkbp:treatment |
improves procedural outcomes
reduces risk of thrombotic events |
| gptkbp:weight |
1040.2 g/mol
|
| gptkbp:bfsParent |
gptkb:Angiomax
|
| gptkbp:bfsLayer |
7
|